U.S. markets closed
  • S&P 500

    +24.65 (+0.58%)
  • Dow 30

    +322.58 (+0.95%)
  • Nasdaq

    +97.98 (+0.69%)
  • Russell 2000

    +29.58 (+1.28%)
  • Crude Oil

    +0.19 (+0.26%)
  • Gold

    -8.80 (-0.49%)
  • Silver

    -0.17 (-0.65%)

    +0.0007 (+0.06%)
  • 10-Yr Bond

    0.0000 (0.00%)

    -0.0032 (-0.23%)

    -0.1140 (-0.10%)

    +2,003.48 (+6.09%)
  • CMC Crypto 200

    +53.90 (+6.85%)
  • FTSE 100

    +35.91 (+0.51%)
  • Nikkei 225

    +0.34 (+0.00%)

Biotech Companies Think Big with Specialization - Fighting Deadly Bacteria and Viruses

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Point Roberts, Washington and Vancouver, British Columbia--(Newsfile Corp. - January 27, 2020) - Investorideas.com, a leading investor news resource covering pharmaceutical and biotechnology stocks releases a special report on the opportunity within the specialty drug segment of the sector to address viral outbreaks and bacterial resistance, featuring Citius Pharmaceuticals, Inc. (NASDAQ: CTXR).

Read the full article on Investorideas.com

Certain social and technological advancements as well as new and deadlier viral (coronavirus) and bacterial outbreaks are forcing innovative business approaches for this competitive sub-sector and specialty companies are answering the call!

Looking at the current headline attention of the coronavirus, Infectioncontroltoday.com also addressed the current crisis of antimicrobial resistance. "Now that the planet's attention is turned toward infectious disease thanks to the spotting of coronavirus in the United States, the World Health Organization (WHO) took the opportunity to point to another problem: the growing shortage of antibiotics available to fight all pathogens."

A WHO press release reported, "Tedros Adhanom Ghebreyesus, PhD, the director-general of WHO, said in the press release that "never has the threat of antimicrobial resistance been more immediate and the need for solutions more urgent. Numerous initiatives are underway to reduce resistance, but we also need countries and the pharmaceutical industry to step up and contribute with sustainable funding and innovative new medicines."

Citius Pharmaceuticals, Inc. (NASDAQ: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products is in the midst of bringing their products to market having recently announced a positive outcome of the pre-specified interim futility analysis for the Phase 3 clinical trial of Mino-Lok® vs. standard-of-care antibiotic locks.

The analysis was conducted by the Mino-Lok trial Data Monitoring Committee ("DMC"), an independent panel of experts charged with periodically monitoring the safety and efficacy of the progress of the pivotal trial. The Company reached and completed the pre-specified 40% enrollment required for the interim futility analysis in late September and, based on the analysis of the data and recommendations of the DMC, will proceed with the current trial as planned. Topline data from the superior efficacy interim analysis, the next major milestone in the Mino-Lok trial, is expected in the first half of 2020. The market potential for an effective antibiotic lock therapy is estimated at $750 million per year in the US and approximately $1.5 billion per year worldwide.

"We are extremely happy and proud that the first independent expert review of the patient data in our Mino-Lok trial concludes that our study is on track. Enrollment has continued since finalizing the 40% level futility report, and we have now reached the midpoint of our study. The DMC will evaluate clinical data at the 75% level of enrollment to see if Mino-Lok demonstrates superior efficacy versus standard-of-care antibiotic locks," said Myron Holubiak, Chief Executive Officer of Citius. "We would also like to thank all of the patients, study investigators, and support personnel at the 32 clinical sites that are participating in our trial. Lastly, we also want to acknowledge the research and guidance of Dr. Issam Raad and his team at MD Anderson Cancer Center in advancing this novel therapy."

Citius Pharmaceuticals, Inc. "Saving Lives of Hospital Patients with Catheters Infected by Deadly Bacteria" :

Citius was recently featured in a recent edition of BiotechStock Review, which discussed the Citius "Mino-Lok" treatment - "created to kill infected catheters, Mino-Lok was developed clinicians and technologists at the M.D. Anderson Cancer Center. The Mini-Lok technology while complex is easy for investors to understand. Their market is huge, estimated at $500 million to $1 billion annually and fairly-easy for investors to identify. The need for Mino-Lok is rather obvious as we will later explain. Also, studies to date have proven it to be much safer, more effective and less expensive than the alternatives and once again, easy for investors to grasp. Finally, the time (they're in Phase III), path and cost to approval are modest in comparison to biotech companies creating drugs from scratch. A 'five-fecta' so to speak."

Continued: "Part of the Citius business strategy is to build a successful company by developing and commercializing cost-effective products that address unmet medical needs. It seeks to leverage the FDA's 505(b)(2) pathway for new drug approvals and bring products to market faster and with lower cost than other FDA new drug approval pathways (meaning creating drugs from scratch)."

Continued "The Mino-Lok solution was created to kill bacteria that cannot be eradicated using current methods, resulting in the catheter needing to be removed and replaced. A dangerous and complicated procedure, Mino-Lok is the first - and only - therapy under investigation that can be used to sterilize and save the infected catheter."

Continued "Mino-Lok is a patented solution that combines Minocycline, an antibiotic from the Tetracycline family with two other well-known ingredients. Minocycline was patented around the time we were born, as in 60 years ago - and prescribed 2 million times last year. It's now a generic costing about $12 a dose. The list of use includes things like Anthrax and even the Bubonic Plague. So were guessing the FDA will recognize both its usefulness and safety profile."

Fusionscienceacademy.com reports, "According to the Centers for Disease Control and Prevention (CDC), the leading federal agency focused on public health in the United States, over two million infections are caused by the antibiotic-resistant bacterial pathogens per year in the country, resulting in around 23,000 deaths."

With antibiotic-resistant bacteria on the rise and new strains of viruses surfacing, opportunity abounds for the smaller specialty drug maker that can provide solutions.

Learn more about biotech stocks at Investorideas.com https://www.investorideas.com/BIS/

About Investorideas.com - News that Inspires Big Investing Ideas Investorideas.com is a recognized news source publishing third party news, research and original financial content. Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea's original branded content includes the following podcasts and columns : Crypto Corner , Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change , Exploring Mining the AI Eye .

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. Disclosure: this news article featuring CTXR is a paid for news release on Investorideas.com - third party (two thousand) More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Contact Investorideas.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/51828